Rifaximin (Sandoz GmbH) tablet + Rifaximin (Xifaxan) + Placebo
Phase 3Terminated 0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Travelers' Diarrhea
Conditions
Travelers' Diarrhea
Trial Timeline
Dec 15, 2016 → May 23, 2017
NCT ID
NCT02920242About Rifaximin (Sandoz GmbH) tablet + Rifaximin (Xifaxan) + Placebo
Rifaximin (Sandoz GmbH) tablet + Rifaximin (Xifaxan) + Placebo is a phase 3 stage product being developed by Sandoz Group for Travelers' Diarrhea. The current trial status is terminated. This product is registered under clinical trial identifier NCT02920242. Target conditions include Travelers' Diarrhea.
What happened to similar drugs?
1 of 1 similar drugs in Travelers' Diarrhea were approved
Approved (1) Terminated (0) Active (0)
Hype Score Breakdown
Clinical
17
Activity
0
Company
12
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02920242 | Phase 3 | Terminated |
Competing Products
1 competing product in Travelers' Diarrhea
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Rifaximin and loperamide | Bausch Health | Approved | 37 |